- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
J. Martin Jernigan, Novo Nordisk
S
J. Martin Jernigan
Associate VP, Liraglutide launch, Novo Nordisk
FIRST DRUG HE DETAILED: Cardizem
PARENTS' JOBS: Minister, Teacher
J &J is the type of company that spends a lot of time thinking about leadership. It was there that J. Martin Jernigan, as head of new business development, learned his own personal leadership style. "I'm much more the cultivator, the grower, the facilitator," he says. "I believe in the servant role of leadership—how can I help you to get your job done? You get better results that way."
This isn't news to anyone who knows Jernigan. While heading new product commercialization for Aventis, he helped create massive, cross-functional, matrix-based teams that offered new ways to bridge science and business. At Novo, his responsibilities have changed, but he's still growing teams and cultivating change. Since joining in 2006, Jernigan has implemented a strategic planning process for the US and is now charged with launching the highly anticipated diabetes drug, liraglutide. "It's challenging from a developmental perspective because it is more of a general manager role. But really, we are just one big team preparing for launch."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
